| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vascular and Interventional Radiology |
1 From the Departments of Radiology (N.M., C.M.T., F.M.F., M.J.S., F.J.R., F.A.J., K.H.) and Obstetrics and Gynecology (E.A.S.), Harvard Medical School, Brigham and Women's Hospital, 221 Longwood Ave (LMRC, 007c), Boston, MA 02115. Received April 28, 2005; revision requested June 22; revision received July 19; accepted August 15; final version accepted September 1. Supported by NIH grants P01CA067165, R25CA089017, and U41RR019703. Clinical trial funded by InSightec, Haifa, Israel. Address correspondence to N.M. (e-mail: njm{at}bwh.harvard.edu).
Purpose: To retrospectively evaluate magnetic resonance (MR) imaging–based thermometry and thermal dosimetry during focused ultrasound treatments of uterine leiomyomas (ie, fibroids).
Materials and Methods: All patients gave written informed consent for the focused ultrasound treatments and the current HIPAA-compliant retrospective study, both of which were institutional review board approved. Thermometry performed during the treatments of 64 fibroids in 50 women (mean age, 46.6 years ± 4.5 [standard deviation]) was used to create thermal dose maps. The areas that reached dose values of 240 and 18 equivalent minutes at 43°C were compared with the nonperfused regions measured on contrast material–enhanced MR images by using the Bland-Altman method. Volume changes in treated fibroids after 6 months were compared with volume changes in nontreated fibroids and with MR-based thermal dose estimates.
Results: While the thermal dose estimates were shown to have a clear relationship with resulting nonperfused regions, the nonperfused areas were, on average, larger than the dose estimates (means of 1.9 ± 0.7 and 1.2 ± 0.4 times as large for areas that reached 240- and 18-minute threshold dose values, respectively). Good correlation was observed for smaller treatment volumes at the lower dose threshold (mean ratio, 1.0 ± 0.3), but for larger treatment volumes, the nonperfused region extended to locations within the fibroid that clearly were not heated. Variations in peak temperature increase were as large as a factor of two, both between patients and within individual treatments. On average, the fibroid volume reduction at 6 months increased as the ablated volume estimated by using the thermal dose increased.
Conclusion: Study results showed good correlation between thermal dose estimates and resulting nonperfused areas for smaller ablated volumes. For larger treatment volumes, nonperfused areas could extend within the fibroid to unheated areas.
© RSNA, 2006
This article has been cited by other articles:
|
|
 |
|
  Z. M. Lenard, N. J. McDannold, F. M. Fennessy, E. A. Stewart, F. A. Jolesz, K. Hynynen, and C. M. C. Tempany Uterine Leiomyomas: MR Imaging-guided Focused Ultrasound Surgery--Imaging Predictors of Success Radiology, October 1, 2008; 249(1): 187 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okuda, K. Oshio, H. Shinmoto, A. Tanimoto, H. Asada, T. Fujii, Y. Yoshimura, and S. Kuribayashi Semiquantitative Assessment of MR Imaging in Prediction of Efficacy of Gonadotropin-releasing Hormone Agonist for Volume Reduction of Uterine Leiomyoma: Initial Experience Radiology, September 1, 2008; 248(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Fennessy, C. M. Tempany, N. J. McDannold, M. J. So, G. Hesley, B. Gostout, H. S. Kim, G. A. Holland, D. A. Sarti, K. Hynynen, et al. Uterine Leiomyomas: MR Imaging-guided Focused Ultrasound Surgery--Results of Different Treatment Protocols Radiology, June 1, 2007; 243(3): 885 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kopelman and M. Papa Magnetic Resonance-Guided Focused Ultrasound Surgery for the Noninvasive Curative Ablation of Tumors and Palliative Treatments: A Review Ann. Surg. Oncol., May 1, 2007; 14(5): 1540 - 1550. [Abstract] [Full Text] [PDF]
|
|
